Mantle cell lymphoma and the evidence of an immature lymphoid component
- PMID: 35286938
- DOI: 10.1016/j.leukres.2022.106824
Mantle cell lymphoma and the evidence of an immature lymphoid component
Abstract
Mantle cell lymphoma (MCL) is a rare B cell malignancy. The classical MCL subtype is positive for translocation t(11;14), SOX11 expression, and characterized as a mature B cell neoplasm. While it is evident that differentiated B lymphocytes comprise the principal constituent of this malignancy, the possibility of an immature component involving immature progenitor, precursor, or even multipotent stem cells exists. It is now known that many hematologic malignancies are preceded by clonal hematopoiesis or a premalignant phase, which may involve early progenitors, and that such mutations can persist following treatment. Here, we thematically review and discuss the existing evidence pointing to an immature contribution of MCL in some cases. With the ongoing transition towards comprehensive genomic profiling, it is now possible to thoroughly investigate whether an immature genomic profile accompanies the morphologically lymphoblastic appearance of the blastoid subtype. This profile may include the expression of genes related to the pre-B cell receptor or genes required for the development and differentiation of B cell progenitors and precursors, such as transcription factor, SOX4, and the terminal transferase, DNTT. Research into the likely immature component of MCL is motivated by the relevance in treatment strategies because such cells potentially constitute a reservoir with increased resistance. In conclusion, further evidence on the concept, and definition, of lymphoma progenitors, precursors, or stem cell involvement in MCL is highly warranted.
Keywords: Lymphoma precursor; Lymphoma progenitor; Lymphoma stem cell; Mantle cell lymphoma.
Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved.
Similar articles
-
Detailed characterization of the transcriptome of single B cells in mantle cell lymphoma suggesting a potential use for SOX4.Sci Rep. 2021 Sep 27;11(1):19092. doi: 10.1038/s41598-021-98560-1. Sci Rep. 2021. PMID: 34580376 Free PMC article.
-
SOX11 regulates PAX5 expression and blocks terminal B-cell differentiation in aggressive mantle cell lymphoma.Blood. 2013 Mar 21;121(12):2175-85. doi: 10.1182/blood-2012-06-438937. Epub 2013 Jan 15. Blood. 2013. PMID: 23321250
-
Gene expression profiling and chromatin immunoprecipitation identify DBN1, SETMAR and HIG2 as direct targets of SOX11 in mantle cell lymphoma.PLoS One. 2010 Nov 22;5(11):e14085. doi: 10.1371/journal.pone.0014085. PLoS One. 2010. PMID: 21124928 Free PMC article.
-
miR-223 is repressed and correlates with inferior clinical features in mantle cell lymphoma through targeting SOX11.Exp Hematol. 2018 Feb;58:27-34.e1. doi: 10.1016/j.exphem.2017.10.005. Epub 2017 Nov 20. Exp Hematol. 2018. PMID: 29158064 Review.
-
Leukemic Variant of Mantle Cell Lymphoma: Clinical Presentation and Management.Curr Oncol Rep. 2021 Jul 16;23(9):102. doi: 10.1007/s11912-021-01094-y. Curr Oncol Rep. 2021. PMID: 34269910 Review.
Cited by
-
The dark side of stemness - the role of hematopoietic stem cells in development of blood malignancies.Front Oncol. 2024 Feb 19;14:1308709. doi: 10.3389/fonc.2024.1308709. eCollection 2024. Front Oncol. 2024. PMID: 38440231 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources